PT2630146T - Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino - Google Patents

Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino

Info

Publication number: PT2630146T
Authority: PT; Portugal
Prior art keywords: phtalazin; crystaline; pyrido; triazol; fluorophenyl
Prior art date: 2010-10-21

Application number

PT117770057T

Other languages

English (en)

Original Assignee

Medivation Tech Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-21

Filing date

2011-10-20

Publication date

2020-07-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2630146(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-20 Application filed by Medivation Tech Llc filed Critical Medivation Tech Llc

2020-07-20 Publication of PT2630146T publication Critical patent/PT2630146T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PT117770057T 2010-10-21 2011-10-20 Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino PT2630146T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US40547610P	2010-10-21	2010-10-21

Publications (1)

Publication Number	Publication Date
PT2630146T true PT2630146T (pt)	2020-07-20

Family

ID=44903424

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT117770057T PT2630146T (pt)	2010-10-21	2011-10-20	Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino

Country Status (24)

Country	Link
US (3)	US8735392B2 (pt)
EP (2)	EP2630146B1 (pt)
JP (6)	JP2013540158A (pt)
KR (4)	KR20180069132A (pt)
CN (1)	CN103282365B (pt)
AR (1)	AR083502A1 (pt)
AU (2)	AU2011317040B2 (pt)
BR (1)	BR112013009117A2 (pt)
CA (1)	CA2814581C (pt)
CY (1)	CY1123356T1 (pt)
DK (1)	DK2630146T3 (pt)
ES (1)	ES2816600T3 (pt)
HU (1)	HUE051535T2 (pt)
IL (2)	IL225789B (pt)
MX (1)	MX362563B (pt)
NZ (1)	NZ609490A (pt)
PL (1)	PL2630146T3 (pt)
PT (1)	PT2630146T (pt)
RU (1)	RU2598606C3 (pt)
SG (2)	SG10201710578TA (pt)
SI (1)	SI2630146T1 (pt)
TW (2)	TWI557123B (pt)
WO (1)	WO2012054698A1 (pt)
ZA (1)	ZA201302810B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2767537T (pt)	2008-08-06	2017-07-17	Medivation Technologies Inc	Inibidores de di-hidropiridoftalazinona de poli(adp-ribose)polimerase (parp)
ES2740424T3 (es)	2009-03-13	2020-02-05	Agios Pharmaceuticals Inc	Métodos y composiciones para trastornos relacionados con la proliferación celular
SG177434A1 (en)	2009-06-29	2012-02-28	Agios Pharmaceuticals Inc	Therapeutic compounds and compositions
ES2594402T3 (es)	2009-10-21	2016-12-20	Agios Pharmaceuticals, Inc.	Métodos y composiciones para trastornos relacionados con la proliferación celular
CN102869258A (zh)	2010-02-03	2013-01-09	生物马林药物股份有限公司	用于pten基因缺失相关疾病的治疗的聚（adp-核糖）聚合酶（parp）的二氢吡啶并酞嗪酮抑制剂
RU2561732C2 (ru)	2010-02-08	2015-09-10	Байомарин Фармасьютикал Инк.	Способы синтеза производных дигидропиридофталазинона
PL2630146T3 (pl)	2010-10-21	2020-11-02	Medivation Technologies Llc	Krystaliczna sól tosylanowa (8S,9R)-5-fluoro-8-(4-fluorofenylo)-9-(1-metylo-1H-1,2,4-triazol-5-ilo)-8,9-dihydro-2H-pirydo[4,3,2-de]ftalazyno-3(7H)-onu
PH12013502241A1 (en)	2011-05-03	2014-01-06	Agios Pharmaceuticals Inc	Pyruvate kinase activators for use in therapy
CN102827170A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
CN102827073A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
US9198432B2 (en) *	2011-08-11	2015-12-01	Bayer Intellectual Property Gmbh	1,2,4-triazolyl-substituted ketoenols
WO2013028495A1 (en) *	2011-08-19	2013-02-28	Biomarin Pharmaceutical Inc.	Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
CA2888360A1 (en)	2012-10-15	2014-04-24	Agios Pharmaceuticals, Inc.	Therapeutic compounds and compositions
US9579324B2 (en)	2013-07-11	2017-02-28	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
WO2015003360A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
WO2015003355A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
AU2014287121B2 (en)	2013-07-11	2018-11-15	Agios Pharmaceuticals, Inc.	2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
SG10201806846RA (en)	2014-02-13	2018-09-27	Incyte Corp	Cyclopropylamines as lsd1 inhibitors
PH12020552066A1 (en)	2014-02-13	2022-05-11	Incyte Corp	Cyclopropylamines as lsd1 inhibitors
DK3116491T3 (da) *	2014-03-14	2021-08-09	Les Laboratoires Servier Sas	Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
WO2015138839A1 (en)	2014-03-14	2015-09-17	Agios Pharmaceuticals, Inc.	Pharmaceutical compositions of therapeutically active compounds
WO2016007722A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
CN107155326B (zh)	2014-07-31	2021-03-05	麦迪韦逊科技有限公司	一种共形成体盐及其制备方法
PH12017501817B1 (en)	2015-04-03	2023-06-16	Incyte Holdings Corp	Heterocyclic compounds as lsd1 inhibitors
EP4344703A1 (en)	2015-06-11	2024-04-03	Agios Pharmaceuticals, Inc.	Methods of using pyruvate kinase activators
TWI765860B (zh)	2015-08-12	2022-06-01	美商英塞特公司	Lsd1抑制劑之鹽
MD3362065T2 (ro)	2015-10-15	2024-08-31	Servier Lab	Terapie combinată care conține ivosidenib, citarabină și daunorubicina sau idarubicina pentru tratarea leucemiei acute mielogene
PT3362066T (pt)	2015-10-15	2021-11-16	Celgene Corp	Terapia de combinação para tratar malignidades
KR20180100546A (ko) *	2015-10-26	2018-09-11	메디베이션 테크놀로지즈 엘엘씨	Parp 저해제를 이용한 소-세포성 폐암의 치료 방법
JP6577143B2 (ja)	2016-02-29	2019-09-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
CA3078806A1 (en)	2017-10-13	2019-04-18	Merck Patent Gmbh	Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW201938165A (zh)	2017-12-18	2019-10-01	美商輝瑞股份有限公司	治療癌症的方法及組合療法
WO2019235822A1 (ko)	2018-06-04	2019-12-12	엘지전자 주식회사	어파인 움직임 예측을 이용하여 비디오 신호를 처리하는 방법 및 장치
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
US10942500B2 (en) *	2018-06-11	2021-03-09	Purdue Research Foundation	System architecture and method of processing data therein
US10284860B1 (en) *	2018-07-02	2019-05-07	Tencent America LLC	Method and apparatus for video coding
CN117369133A (zh)	2018-07-13	2024-01-09	奇跃公司	用于显示双目变形补偿的系统和方法
WO2020047198A1 (en)	2018-08-31	2020-03-05	Incyte Corporation	Salts of an lsd1 inhibitor and processes for preparing the same
WO2020095184A1 (en)	2018-11-05	2020-05-14	Pfizer Inc.	Combinations for treating cancer
EP4118105A2 (en)	2020-03-09	2023-01-18	Pfizer Inc.	Cd80-fc fusion protein and uses thereof
US20230414522A1 (en)	2020-11-13	2023-12-28	Pfizer Inc.	Talazoparib soft gelatin capsule dosage form
US20240052423A1 (en)	2020-12-07	2024-02-15	Pfizer Inc.	Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
CA3214316A1 (en)	2021-03-24	2022-09-29	Pfizer Inc.	Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
WO2023131894A1 (en)	2022-01-08	2023-07-13	Pfizer Inc.	Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en)	2022-04-15	2023-10-19	Ideaya Biosciences, Inc.	Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en)	2022-06-01	2023-12-07	Ideaya Biosciences, Inc.	Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
TW202425975A (zh)	2022-10-02	2024-07-01	美商輝瑞大藥廠	用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh)	2022-12-17	2024-07-01	美商輝瑞大藥廠	用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4415504A (en)	1981-09-21	1983-11-15	Tanabe Seiyaku Co., Ltd.	p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja)	1982-06-21	1983-12-27	Nippon Shinyaku Co Ltd	２−キノロン誘導体
US5328905A (en)	1987-07-20	1994-07-12	Duphar International Research B.V.	8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
GB9505538D0 (en)	1995-03-18	1995-05-03	Ciba Geigy Ag	New compounds
ID19155A (id)	1996-12-13	1998-06-18	Tanabe Seiyaku Co	Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de)	1997-06-27	1999-01-07	Hoechst Schering Agrevo Gmbh	3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en)	1997-09-03	2003-02-04	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en)	1997-12-03	2001-04-21	Dainippon Ink & Chemicals	Quinolinone derivative, method for preparing the same, and anti-allergic agent
EP1077946A1 (en)	1998-05-15	2001-02-28	Guilford Pharmaceuticals Inc.	Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de)	1999-05-11	2000-11-16	Basf Ag	Verwendung von Phthalazine-Derivaten
JP2001302669A (ja)	2000-04-18	2001-10-31	Meiji Seika Kaisha Ltd	三環性フタラジノン誘導体
JP2002284699A (ja)	2001-03-28	2002-10-03	Sumitomo Pharmaceut Co Ltd	視細胞変性疾患治療剤
AR036081A1 (es)	2001-06-07	2004-08-11	Smithkline Beecham Corp	Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv)	2001-06-28	2001-06-28	Astrazeneca Ab	Compounds
EP1477175B1 (en) *	2002-02-19	2011-04-27	Ono Pharmaceutical Co., Ltd.	Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
EP1340819A1 (en)	2002-02-28	2003-09-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Microsatellite markers
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
EP1400244A1 (en)	2002-09-17	2004-03-24	Warner-Lambert Company LLC	New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
AU2003277674A1 (en)	2002-11-12	2004-06-03	Mochida Pharmaceutical Co., Ltd.	Novel parp inhibitors
MXPA05009661A (es)	2003-03-12	2006-03-08	Kudos Pharm Ltd	Derivados de ftalazinona.
US7268138B2 (en)	2003-05-28	2007-09-11	Mgi Gp, Inc.	Compounds, methods and pharmaceutical compositions for inhibiting PARP
MY145075A (en)	2004-02-18	2011-12-15	Astrazeneca Ab	Tetrazole compounds and their use as metabotropic glutamate receptor antagonists.
GB0612971D0 (en)	2006-06-30	2006-08-09	Angeletti P Ist Richerche Bio	Therapeutic compounds
US8198448B2 (en)	2006-07-14	2012-06-12	Amgen Inc.	Fused heterocyclic derivatives and methods of use
GEP20125379B (en)	2007-05-03	2012-01-10	Pfizer Ltd	2 -pyridine carboxamide derivatives as sodium channel modulators
CA2697246A1 (en)	2007-08-22	2009-02-26	4Sc Ag	Indolopyridines as inhibitors of the kinesin spindle protein (eg5)
CN101998959B (zh)	2008-02-06	2013-08-28	生物马林药物股份有限公司	聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
PT2767537T (pt)	2008-08-06	2017-07-17	Medivation Technologies Inc	Inibidores de di-hidropiridoftalazinona de poli(adp-ribose)polimerase (parp)
KR20110053424A (ko)	2008-08-12	2011-05-23	베링거 인겔하임 인터내셔날 게엠베하	사이클로알킬-치환된 피페라진 화합물의 제조 방법
CN102869258A (zh)	2010-02-03	2013-01-09	生物马林药物股份有限公司	用于pten基因缺失相关疾病的治疗的聚（adp-核糖）聚合酶（parp）的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en)	2010-02-04	2011-08-04	Daniel Chu	5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
RU2561732C2 (ru)	2010-02-08	2015-09-10	Байомарин Фармасьютикал Инк.	Способы синтеза производных дигидропиридофталазинона
WO2011130661A1 (en)	2010-04-16	2011-10-20	Biomarin Pharmaceutical Inc.	Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en)	2010-05-04	2011-11-10	Biomarin Pharmaceutical Inc.	Methods of using semi-synthetic glycopeptides as antibacterial agents
PL2630146T3 (pl)	2010-10-21	2020-11-02	Medivation Technologies Llc	Krystaliczna sól tosylanowa (8S,9R)-5-fluoro-8-(4-fluorofenylo)-9-(1-metylo-1H-1,2,4-triazol-5-ilo)-8,9-dihydro-2H-pirydo[4,3,2-de]ftalazyno-3(7H)-onu
WO2012166151A1 (en)	2011-06-03	2012-12-06	Biomarin Pharmaceutical Inc.	Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en)	2011-08-19	2013-02-28	Biomarin Pharmaceutical Inc.	Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en)	2011-08-30	2013-02-28	Biomarin Pharmaceutical, Inc.	Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
EP3066084A1 (en)	2013-11-07	2016-09-14	Medivation Technologies, Inc.	Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
CN107155326B (zh)	2014-07-31	2021-03-05	麦迪韦逊科技有限公司	一种共形成体盐及其制备方法

2011
- 2011-10-20 PL PL11777005T patent/PL2630146T3/pl unknown
- 2011-10-20 EP EP11777005.7A patent/EP2630146B1/en active Active
- 2011-10-20 MX MX2013004195A patent/MX362563B/es active IP Right Grant
- 2011-10-20 CN CN201180062085.0A patent/CN103282365B/zh active Active
- 2011-10-20 KR KR1020187016905A patent/KR20180069132A/ko active Application Filing
- 2011-10-20 BR BR112013009117A patent/BR112013009117A2/pt not_active Application Discontinuation
- 2011-10-20 CA CA2814581A patent/CA2814581C/en active Active
- 2011-10-20 KR KR1020197030773A patent/KR20190120458A/ko not_active Application Discontinuation
- 2011-10-20 KR KR1020217006784A patent/KR20210028747A/ko not_active Application Discontinuation
- 2011-10-20 SI SI201131903T patent/SI2630146T1/sl unknown
- 2011-10-20 AU AU2011317040A patent/AU2011317040B2/en active Active
- 2011-10-20 ES ES11777005T patent/ES2816600T3/es active Active
- 2011-10-20 AR ARP110103892A patent/AR083502A1/es not_active Application Discontinuation
- 2011-10-20 JP JP2013535079A patent/JP2013540158A/ja active Pending
- 2011-10-20 US US13/277,607 patent/US8735392B2/en active Active
- 2011-10-20 DK DK11777005.7T patent/DK2630146T3/da active
- 2011-10-20 EP EP20175014.8A patent/EP3757106A1/en not_active Withdrawn
- 2011-10-20 NZ NZ609490A patent/NZ609490A/en unknown
- 2011-10-20 KR KR1020137012297A patent/KR20140009181A/ko active Application Filing
- 2011-10-20 SG SG10201710578TA patent/SG10201710578TA/en unknown
- 2011-10-20 TW TW100138150A patent/TWI557123B/zh active
- 2011-10-20 RU RU2013123036A patent/RU2598606C3/ru active Protection Beyond IP Right Term
- 2011-10-20 PT PT117770057T patent/PT2630146T/pt unknown
- 2011-10-20 SG SG2013029731A patent/SG189939A1/en unknown
- 2011-10-20 HU HUE11777005A patent/HUE051535T2/hu unknown
- 2011-10-20 WO PCT/US2011/057039 patent/WO2012054698A1/en active Application Filing
- 2011-10-20 TW TW105123467A patent/TWI643858B/zh active
2013
- 2013-04-17 IL IL225789A patent/IL225789B/en active IP Right Grant
- 2013-04-18 ZA ZA2013/02810A patent/ZA201302810B/en unknown
2014
- 2014-04-14 US US14/252,668 patent/US20140228369A1/en not_active Abandoned
2016
- 2016-11-18 JP JP2016224670A patent/JP2017061526A/ja active Pending
2017
- 2017-03-07 AU AU2017201564A patent/AU2017201564B2/en active Active
- 2017-07-17 US US15/651,735 patent/US10189837B2/en active Active
2018
- 2018-10-11 JP JP2018192521A patent/JP2019034951A/ja not_active Withdrawn
2019
- 2019-12-17 IL IL271497A patent/IL271497A/en unknown
2020
- 2020-07-09 JP JP2020118281A patent/JP2020169209A/ja not_active Withdrawn
- 2020-09-22 CY CY20201100893T patent/CY1123356T1/el unknown
2022
- 2022-08-02 JP JP2022123448A patent/JP2022140637A/ja not_active Withdrawn
2024
- 2024-08-07 JP JP2024130494A patent/JP2024150772A/ja active Pending

Also Published As

Publication number	Publication date
AU2017201564A1 (en)	2017-03-23
ZA201302810B (en)	2014-06-25
BR112013009117A2 (pt)	2016-07-19
AU2011317040B2 (en)	2016-12-08
KR20140009181A (ko)	2014-01-22
JP2019034951A (ja)	2019-03-07
SG10201710578TA (en)	2018-02-27
JP2024150772A (ja)	2024-10-23
MX2013004195A (es)	2013-07-22
TW201713656A (en)	2017-04-16
CA2814581A1 (en)	2012-04-26
IL225789A0 (en)	2013-06-27
TWI643858B (zh)	2018-12-11
KR20210028747A (ko)	2021-03-12
WO2012054698A1 (en)	2012-04-26
HUE051535T2 (hu)	2021-03-01
EP2630146B1 (en)	2020-07-01
TW201307345A (zh)	2013-02-16
JP2020169209A (ja)	2020-10-15
US20140228369A1 (en)	2014-08-14
US20180009806A1 (en)	2018-01-11
US20120129865A1 (en)	2012-05-24
EP2630146A1 (en)	2013-08-28
AU2017201564B2 (en)	2019-05-09
CN103282365B (zh)	2017-12-29
IL271497A (en)	2020-02-27
JP2017061526A (ja)	2017-03-30
RU2598606C2 (ru)	2016-09-27
EP3757106A1 (en)	2020-12-30
JP2013540158A (ja)	2013-10-31
AU2011317040A1 (en)	2013-05-09
RU2013123036A (ru)	2014-11-27
RU2598606C3 (ru)	2021-12-20
IL225789B (en)	2019-12-31
CA2814581C (en)	2019-02-12
MX362563B (es)	2019-01-25
JP2022140637A (ja)	2022-09-26
US8735392B2 (en)	2014-05-27
CY1123356T1 (el)	2021-12-31
SG189939A1 (en)	2013-06-28
ES2816600T3 (es)	2021-04-05
PL2630146T3 (pl)	2020-11-02
TWI557123B (zh)	2016-11-11
AR083502A1 (es)	2013-02-27
KR20180069132A (ko)	2018-06-22
US10189837B2 (en)	2019-01-29
SI2630146T1 (sl)	2020-12-31
CN103282365A (zh)	2013-09-04
KR20190120458A (ko)	2019-10-23
NZ609490A (en)	2015-06-26
DK2630146T3 (da)	2020-08-10

Publication	Publication Date	Title
IL271497A (en)	2020-02-27	Tosylate salt of (S8, R9)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-H1- 4,2,1-triazol-5-yl)-9,8-dihydro-H2 -Crystalline pyrido[2,3,4-de]phthalazine-3(H3)-one
ZA201209632B (en)	2014-03-26	Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
PL2477648T3 (pl)	2022-11-07	Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych
ZA201300100B (en)	2014-03-26	Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
ZA201302271B (en)	2014-09-25	Controlled motorized brewing unit
EP2619203A4 (en)	2014-04-16	TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
IL218490A0 (en)	2012-04-30	Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
EP2549947A4 (en)	2015-09-02	COMPOSITE THREE DIMENSIONAL SURGICAL IMPLANT
PL2616065T3 (pl)	2018-05-30	GLIKO-PODSTAWIONE DIHYDROKSYCHLORYNY I ß-FUNKCJONALIZOWANE CHLORYNY DO PRZECIWDROBNOUSTROJOWEJ TERAPII FOTODYNAMICZNEJ
EP2552833A4 (en)	2017-03-15	Surface-modified zeolites and methods for preparing the same
IL229993A (en)	2015-10-29	8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
IL222080B (en)	2018-05-31	6-alkyl-thieno[2,3-c]quinolin-4(5h)-one derivatives
EP2624834A4 (en)	2014-09-17	LACTONE-BASED MACROCYCLIC COMPOUNDS AND METHODS OF USE
IL215286A0 (en)	2011-11-30	9h-pyrrolo[2,3-b:5,4-c]dipridine azacarboline derivatives, preparation thereof, and therapeutic use thereof
IL220448A (en)	2015-04-30	Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses
HK1185882A1 (en)	2014-02-28	Pyrazino[2,3-d]isoxazole derivative [23-d]
IL236808B (en)	2018-05-31	Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
ZA201303580B (en)	2014-12-23	Oxazolo [5,4-b]pyridin-5-yl compounds and their use for the treatment of cancer
PL2477990T3 (pl)	2015-02-27	Pochodne 5-fenylopirazolopirydyny, ich wytwarzanie oraz ich zastosowanie terapeutyczne
EP2651937B8 (en)	2016-07-13	Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
IL226388A0 (en)	2013-07-31	New indolizine derivatives, their preparation and medical use
EP2621490A4 (en)	2014-04-02	PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF
AU2010902149A0 (en)	2010-06-03	Safe drink detector
AU2010900022A0 (en)	2010-01-21	Adjustable body stimulator